Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 2/20 | 0.36 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.36 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.36 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.36 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.36 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.36 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.36 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.36 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.36 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774009 | 0.86 | PRKCA (0.47) | PRKCAMMP12POLBNR1I2SCN9A | |
| SCHEMBL773281 | 0.85 | HPGD (0.42) | PRKCAMMP12POLBNR1I2SCN9A | |
| SCHEMBL10283558 | 0.85 | PRKCA (0.34) | PRKCAMMP12CHRNB4CHRNA3NR1I2 | |
| SCHEMBL793023 | 0.84 | PRKCA (0.36) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL792879 | 0.84 | PRKCA (0.38) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL804242 | 0.83 | PRKCA (0.36) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL792437 | 0.79 | PRKCA (0.47) | PRKCAMMP12PIK3CDPIK3CAPIK3CB | |
| SCHEMBL792596 | 0.78 | PRKCA (0.34) | PRKCAMMP12NR1I2SCN9AALDH1A1 | |
| SCHEMBL792715 | 0.77 | DRD2 (0.36) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL792640 | 0.77 | PRKCA (0.39) | PRKCAMMP12POLBNR1I2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CACNB4 4785/4885CACNA1A 3373/4885CACNA1G 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.